<DOC>
	<DOCNO>NCT01363089</DOCNO>
	<brief_summary>This open label , two way crossover study healthy male subject . Two treatment administer subject , one treatment per study period , randomized manner . Subjects remain resident Clinical Unit even Day 1 morning Day 2 period washout period least 2 day treatment . A post study medical examination perform prior discharge Period 2 . The objective study ass effect single dose intranasal oxymetazoline hydrochloride pharmacokinetics intranasal ketorolac healthy male subject .</brief_summary>
	<brief_title>Study Assess PK Ketorolac Tromethamine Intranasal Assess Effects Oxymetazoline Hydrochloride PK Ketorolac Tromethamine</brief_title>
	<detailed_description />
	<mesh_term>Ketorolac</mesh_term>
	<mesh_term>Ketorolac Tromethamine</mesh_term>
	<mesh_term>Oxymetazoline</mesh_term>
	<mesh_term>Phenylephrine</mesh_term>
	<criteria>Subject male age 18 62 year inclusive Male subject female partner child bear potential must consent use medically acceptable method contraception ( oral implant contraceptive hormone , intrauterine device surgical sterilization plus condom diaphragm spermicidal agent ) throughout study period Subject give sign informed consent Subject within 20 % normal weight height body build accord table `` Desirable Weights Men Women '' ( Metropolitan Life Insurance Co. 1999 ) Subject 's medical history consider normal , clinically significant abnormality Subject consider good health opinion Investigator , determine prestudy physical examination clinically significant abnormality , vital sign within normal range electrocardiogram ( ECG ) clinically significant abnormality Subject 's prestudy clinical laboratory finding within normal range outside normal range deem clinically significant opinion Investigator Subject bilateral patent nasal airway screen Day 1 assess Investigator Subject body weight least 60 kg Subject clinically significant illness 4 week screen Subject use prescribed medication 3 week prior dose counter preparation 7 day prior dose , except paracetamol allow 48 hour ( h ) prior dose . Use multivitamins permit Subject significant history drug/solvent abuse , positive drug abuse test screening Subject history alcohol abuse currently drink excess 28 unit per week Subject currently use tobacco history smoking within past 5 year Subject opinion Investigator suitable participate study Subject participate clinical study investigational drug/device within 3 month prior dose Subject positive human immunodeficiency virus ( HIV ) , hepatitis B hepatitis C screen Subject serious adverse reaction significant hypersensitivity drug Subject donate 500 mL blood within 3 month prior screen Subject history coexist nasal polyp , NSAID sensitivity asthma Subject allergic reaction aspirin NSAIDs Subject currently upper respiratory tract infection respiratory tract condition could interfere absorption nasal spray assessment AEs Subject suspicion rhinitis medicamentosa ( chronic daily use topical decongestant ) Subject use monoamine oxidase inhibitor 14 day prior study entry Subject active peptic ulcer disease , gastrointestinal bleeding perforation , history peptic ulcer disease gastrointestinal bleeding Subject anemia due unexplained known gastrointestinal bleeding Subject history asthma chronic pulmonary disorder Subject renal impairment risk renal failure due volume depletion Subject previous history nasal surgery</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>62 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>